

Hans Rr BrunnstrÄŸm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1150000/publications.pdf>

Version: 2024-02-01

99
papers

5,887
citations

172457

29
h-index

88630

70
g-index

110
all docs

110
docs citations

110
times ranked

12253
citing authors

#	ARTICLE	IF	CITATIONS
1	Reference standards for gene fusion molecular assays on cytological samples: an international validation study. <i>Journal of Clinical Pathology</i> , 2023, 76, 47-52.	2.0	9
2	Difficulties in diagnostics of lung tumours in biopsies: an interpathologist concordance study evaluating the international diagnostic guidelines. <i>Journal of Clinical Pathology</i> , 2022, 75, 302-309.	2.0	7
3	Genome-wide interaction analysis identified low-frequency variants with sex disparity in lung cancer risk. <i>Human Molecular Genetics</i> , 2022, 31, 2831-2843.	2.9	4
4	lam hiQâ€”a novel pair of accuracy indices for imputed genotypes. <i>BMC Bioinformatics</i> , 2022, 23, 50.	2.6	2
5	Feasibility of EBUS-TBNA for histopathological and molecular diagnostics of NSCLCâ€”A retrospective single-center experience. <i>PLoS ONE</i> , 2022, 17, e0263342.	2.5	3
6	Ciliated (FOXJ1+) Cells Display Reduced Ferritin Light Chain in the Airways of Idiopathic Pulmonary Fibrosis Patients. <i>Cells</i> , 2022, 11, 1031.	4.1	3
7	PD-L1 Expression in Non-Small Cell Lung Cancer Specimens: Association with Clinicopathological Factors and Molecular Alterations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4517.	4.1	7
8	Interventional and EBUS cytology in Sweden. <i>Seminars in Diagnostic Pathology</i> , 2022, , .	1.5	0
9	Predictive molecular pathology in the time of coronavirus disease (COVID-19) in Europe. <i>Journal of Clinical Pathology</i> , 2021, 74, 391-395.	2.0	17
10	A gene expressionâ€”based single sample predictor of lung adenocarcinoma molecular subtype and prognosis. <i>International Journal of Cancer</i> , 2021, 148, 238-251.	5.1	10
11	Integration of multiomic annotation data to prioritize and characterize inflammation and immuneâ€”related risk variants in squamous cell lung cancer. <i>Genetic Epidemiology</i> , 2021, 45, 99-114.	1.3	7
12	Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 151, 53-59.	2.0	17
13	Causal relationships between body mass index, smoking and lung cancer: Univariable and multivariable Mendelian randomization. <i>International Journal of Cancer</i> , 2021, 148, 1077-1086.	5.1	73
14	Comprehensive functional annotation of susceptibility variants identifies genetic heterogeneity between lung adenocarcinoma and squamous cell carcinoma. <i>Frontiers of Medicine</i> , 2021, 15, 275-291.	3.4	21
15	Higher concordance of PDâ€”L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma. <i>Cancer Cytopathology</i> , 2021, 129, 468-478.	2.4	4
16	Resolving the biological paradox of aneurysm formation in children with tuberous sclerosis complex. <i>JVS Vascular Science</i> , 2021, 2, 72-78.	1.1	2
17	Clinical significance of RBM3 expression in surgically treated colorectal lung metastases and paired primary tumors. <i>Journal of Surgical Oncology</i> , 2021, 123, 1144-1156.	1.7	3
18	PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2577-2587.	4.2	14

#	ARTICLE	IF	CITATIONS
19	The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types. <i>EBioMedicine</i> , 2021, 65, 103269.	6.1	25
20	Genome-wide association meta-analysis identifies pleiotropic risk loci for aerodigestive squamous cell cancers. <i>PLoS Genetics</i> , 2021, 17, e1009254.	3.5	19
21	Distinct types of plexiform lesions identified by synchrotron-based phase-contrast micro-CT. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 321, L17-L28.	2.9	19
22	Protein Signatures of Remodeled Airways in Transplanted Lungs with Bronchiolitis Obliterans Syndrome Obtained Using Laser-Capture Microdissection. <i>American Journal of Pathology</i> , 2021, 191, 1398-1411.	3.8	3
23	PD-L1 Testing in Cytological Non-Small Cell Lung Cancer Specimens: A Comparison with Biopsies and Review of the Literature. <i>Acta Cytologica</i> , 2021, 65, 501-509.	1.3	9
24	FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response. <i>European Journal of Cancer</i> , 2021, 151, 136-149.	2.8	20
25	Infiltration of NK and plasma cells is associated with a distinct immune subset in non-small cell lung cancer. <i>Journal of Pathology</i> , 2021, 255, 243-256.	4.5	17
26	Factors Influencing Concordance of PD-L1 Expression between Biopsies and Cytological Specimens in Non-Small Cell Lung Cancer. <i>Diagnostics</i> , 2021, 11, 1927.	2.6	4
27	TGF- β -mediated epithelial-mesenchymal transition and tumor-promoting effects in CMT64 cells are reflected in the transcriptomic signature of human lung adenocarcinoma. <i>Scientific Reports</i> , 2021, 11, 22380.	3.3	5
28	Real-World Diagnostic Accuracy and Use of Immunohistochemical Markers in Lung Cancer Diagnostics. <i>Biomolecules</i> , 2021, 11, 1721.	4.0	2
29	Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. <i>Nature Cancer</i> , 2021, 2, 1224-1242.	13.2	37
30	Pulmonary arterial hypertension in systemic sclerosis when criteria and pathobiology differ. <i>Rheumatology</i> , 2020, 59, 1177-1179.	1.9	2
31	Synchrotron-based phase-contrast micro-CT as a tool for understanding pulmonary vascular pathobiology and the 3-D microanatomy of alveolar capillary dysplasia. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 318, L65-L75.	2.9	38
32	Transcriptome-wide association study reveals candidate causal genes for lung cancer. <i>International Journal of Cancer</i> , 2020, 146, 1862-1878.	5.1	33
33	Genome-wide association study of INDELs identified four novel susceptibility loci associated with lung cancer risk. <i>International Journal of Cancer</i> , 2020, 146, 2855-2864.	5.1	7
34	Diagnostic Value of Insulinoma-Associated Protein 1 (INSM1) and Comparison With Established Neuroendocrine Markers in Pulmonary Cancers. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1075-1085.	2.5	38
35	Clinical Utility of Targeted Sequencing in Lung Cancer: Experience From an Autonomous Swedish Health Care Center. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100013.	1.1	4
36	Methylation Patterns and Chromatin Accessibility in Neuroendocrine Lung Cancer. <i>Cancers</i> , 2020, 12, 2003.	3.7	5

#	ARTICLE	IF	CITATIONS
37	A new efficient method to detect genetic interactions for lung cancer GWAS. BMC Medical Genomics, 2020, 13, 162.	1.5	3
38	Successful lung transplantation in a patient with rheumatoid arthritis suffering from obliterative bronchiolitis. Scandinavian Journal of Rheumatology, 2020, 49, 334-335.	1.1	2
39	Protein-altering germline mutations implicate novel genes related to lung cancer development. Nature Communications, 2020, 11, 2220.	12.8	31
40	Comprehensive analysis of RNA binding motif protein 3 (RBM3) in non-small cell lung cancer. Cancer Medicine, 2020, 9, 5609-5619.	2.8	10
41	ASCL1 promotes tumor progression through cell-autonomous signaling and immune modulation in a subset of lung adenocarcinoma. Cancer Letters, 2020, 489, 121-132.	7.2	8
42	Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm. Scandinavian Journal of Clinical and Laboratory Investigation, 2020, 80, 360-369.	1.2	5
43	Typical and atypical carcinoid tumors of the lung: a clinicopathological correlation of 783 cases with emphasis on histological features. Human Pathology, 2020, 98, 98-109.	2.0	8
44	Association Analysis of Driver Gene-Related Genetic Variants Identified Novel Lung Cancer Susceptibility Loci with 20,871 Lung Cancer Cases and 15,971 Controls. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1423-1429.	2.5	6
45	A clonal expression biomarker associates with lung cancer mortality. Nature Medicine, 2019, 25, 1540-1548.	30.7	75
46	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
47	Elevated Platelet Count Appears to Be Causally Associated with Increased Risk of Lung Cancer: A Mendelian Randomization Analysis. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 935-942.	2.5	21
48	Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC. Journal of Thoracic Oncology, 2019, 14, 628-640.	1.1	54
49	Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence. Acta Oncologica, 2019, 58, 1079-1086.	1.8	18
50	Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development. Oncotarget, 2019, 10, 1760-1774.	1.8	25
51	A combined gene expression tool for parallel histological prediction and gene fusion detection in non-small cell lung cancer. Scientific Reports, 2019, 9, 5207.	3.3	17
52	Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancer. Scientific Reports, 2019, 9, 1319.	3.3	11
53	P1.14-37 Lung Cancer in Never-Smokers: A Nationwide Population Based Mapping of Targetable Alterations. Journal of Thoracic Oncology, 2019, 14, S568-S569.	1.1	1
54	Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium. BMJ: British Medical Journal, 2019, 364, k4981.	2.3	36

#	ARTICLE	IF	CITATIONS
55	Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. <i>Lung Cancer</i> , 2019, 130, 50-58.	2.0	127
56	Haem iron intake and risk of lung cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. <i>European Journal of Clinical Nutrition</i> , 2019, 73, 1122-1132.	2.9	17
57	Immunohistochemical profiles in primary lung cancers and epithelial pulmonary metastases. <i>Human Pathology</i> , 2019, 84, 221-230.	2.0	39
58	Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer. <i>International Journal of Cancer</i> , 2018, 143, 1741-1752.	5.1	65
59	Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. <i>Carcinogenesis</i> , 2018, 39, 336-346.	2.8	29
60	Thymoma: a clinicopathological correlation of 1470 cases. <i>Human Pathology</i> , 2018, 73, 7-15.	2.0	54
61	Comparison of Three Different TTF-1 Clones in Resected Primary Lung Cancer and Epithelial Pulmonary Metastases. <i>American Journal of Clinical Pathology</i> , 2018, 150, 533-544.	0.7	27
62	Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. <i>Nature Communications</i> , 2018, 9, 3927.	12.8	43
63	An Integrative Analysis of Transcriptome and Epigenome Features of ASCL1-Positive Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1676-1691.	1.1	21
64	94P Lung cancer recurrence in patients with preoperative circulating tumor DNA and elevated tumor markers. <i>Journal of Thoracic Oncology</i> , 2018, 13, S52-S53.	1.1	0
65	Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. <i>Nature Communications</i> , 2018, 9, 3221.	12.8	60
66	An integrative transcriptome analysis reveals a functional role for thyroid transcription factor 1 in small cell lung cancer. <i>Journal of Pathology</i> , 2018, 246, 154-165.	4.5	17
67	Circulating cotinine concentrations and lung cancer risk in the Lung Cancer Cohort Consortium (LC3). <i>International Journal of Epidemiology</i> , 2018, 47, 1760-1771.	1.9	15
68	Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters. <i>Modern Pathology</i> , 2017, 30, 964-977.	5.5	17
69	Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1257-1267.	1.1	43
70	Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature Genetics</i> , 2017, 49, 1126-1132.	21.4	472
71	Targeted sequencing may facilitate differential diagnostics of pulmonary tumours: a case series. <i>Diagnostic Pathology</i> , 2017, 12, 31.	2.0	7
72	A pathology atlas of the human cancer transcriptome. <i>Science</i> , 2017, 357, .	12.6	2,570

#	ARTICLE	IF	CITATIONS
73	PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. <i>Modern Pathology</i> , 2017, 30, 1411-1421.	5.5	151
74	Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 34796-34810.	1.8	45
75	PD-L1 immunohistochemistry in clinical diagnostics: Inter-pathologist variability is as high as assay variability.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20637-e20637.	1.6	1
76	Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study. <i>PLoS ONE</i> , 2017, 12, e0177875.	2.5	79
77	CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma. <i>PLoS ONE</i> , 2017, 12, e0186284.	2.5	26
78	Various Antibody Clones of Napsin A, Thyroid Transcription Factor 1, and p40 and Comparisons With Cytokeratin 5 and p63 in Histopathologic Diagnostics of Non-Small Cell Lung Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, 648-659.	1.2	26
79	Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer. <i>BMC Cancer</i> , 2016, 16, 603.	2.6	33
80	The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs. <i>Journal of Thoracic Oncology</i> , 2016, 11, 862-872.	1.1	70
81	Profiling cancer testis antigens in non-small-cell lung cancer. <i>JCI Insight</i> , 2016, 1, e86837.	5.0	82
82	Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer. <i>Oncotarget</i> , 2015, 6, 22028-22037.	1.8	61
83	Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome. <i>Clinical Cancer Research</i> , 2014, 20, 6127-6140.	7.0	91
84	Lack of supportive evidence for the use of immunohistochemical staining to identify occult regional lymph node metastases in primary lung cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 429-434.	2.8	1
85	History of depression prior to Alzheimer's disease and vascular dementia verified post-mortem. <i>Archives of Gerontology and Geriatrics</i> , 2013, 56, 80-84.	3.0	21
86	Immunohistochemistry in the Differential Diagnostics of Primary Lung Cancer. <i>American Journal of Clinical Pathology</i> , 2013, 140, 37-46.	0.7	56
87	Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 738-744.	2.7	22
88	Histological specificity of alterations and expression of <i>KIT</i> and <i>KITLG</i> in non-small cell lung carcinoma. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 1088-1096.	2.8	17
89	Dachshund 2 protein, a novel neuroendocrine marker associated with favorable tumor characteristics and clinical outcome in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14580-e14580.	1.6	0
90	Staging of Lewy-related pathology in dementia. , 2012, 31, 216-223.		7

#	ARTICLE	IF	CITATIONS
91	Comparison of four neuropathological scales for Alzheimer's disease. , 2011, 30, 56-69.		15
92	Differential degeneration of the locus coeruleus in dementia subtypes. , 2011, 30, 104-110.		46
93	Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses. Alzheimer's and Dementia, 2010, 6, 104-109.	0.8	31
94	The Accuracy of Short Clinical Rating Scales in Neuropathologically Diagnosed Dementia. American Journal of Geriatric Psychiatry, 2010, 18, 810-820.	1.2	8
95	A 76-YEAR-OLD MAN WITH COGNITIVE AND NEUROLOGICAL SYMPTOMS. Brain Pathology, 2009, 19, 731-734.4.1		3
96	Cause of death in patients with dementia disorders. European Journal of Neurology, 2009, 16, 488-492.	3.3	194
97	Prevalence of dementia subtypes: A 30-year retrospective survey of neuropathological reports. Archives of Gerontology and Geriatrics, 2009, 49, 146-149.	3.0	118
98	Clinicopathological Concordance in Dementia Diagnostics. American Journal of Geriatric Psychiatry, 2009, 17, 664-670.	1.2	60
99	Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells. Oncogene, 2004, 23, 4050-4059.	5.9	66